# DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

> **NCT07544654** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 390 (estimated)

## Conditions studied

- Extrapulmonary Neuroendocrine Cancer

## Interventions

- **DRUG:** Obrixtamig
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DEVICE:** Ventana DLL3 RxDx assay

## Key facts

- **NCT ID:** NCT07544654
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2029-12-13
- **Final completion:** 2029-12-13
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07544654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07544654, "DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07544654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*